<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020344</url>
  </required_header>
  <id_info>
    <org_study_id>COPD-CVD2</org_study_id>
    <nct_id>NCT01020344</nct_id>
  </id_info>
  <brief_title>Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Randomized Controlled Trial on the Cardiovascular Effects of Lung Volume Reduction Surgery in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled trial will be performed to evaluate the effects of lung volume&#xD;
      reduction surgery (LVRS) in patients with COPD on systemic inflammation, oxidative stress,&#xD;
      endothelial function, arterial stiffness and blood pressure. We hypothesize that LVRS will&#xD;
      lead to a reduction of systemic inflammation, oxidative stress, arterial stiffness and blood&#xD;
      pressure and to improved endothelial function.&#xD;
&#xD;
      For this purpose 30 patients with severe/very severe COPD (GOLD III-IV) and pulmonary&#xD;
      emphysema who are to undergo LVRS will be randomised to one of two groups: group 1 receiving&#xD;
      immediate LVRS and group 2 receiving LVRS after a delay of 3 months.&#xD;
&#xD;
      Measures of systemic inflammation, oxidative stress, endothelial function, arterial stiffness&#xD;
      and blood pressure will be measured at baseline and 3 months after surgery and no surgery,&#xD;
      respectively (group 2 receiving surgery only after a delay of 3 months will serve as control&#xD;
      group) to investigate the effects of LVRS on the described outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not desired&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Systemic inflammation 2. Vascular function</measure>
    <time_frame>Before and 3 months after surgery/no surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Oxidative stress 2. Blood pressure 3. Physical Activity 4. Lung function 5. Hypoxemia</measure>
    <time_frame>Before and 3 months after surgery/no surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Lung volume reduction surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive lung volume reduction surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No lung volume reduction surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive LVRS during the 3 months of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung volume reduction surgery</intervention_name>
    <description>Lung volume reduction surgery</description>
    <arm_group_label>Lung volume reduction surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Dyspnea at rest or at minimal physical activity, severe limitation of exercise&#xD;
             capacity (6-min walk distance &lt; 350 m).&#xD;
&#xD;
          -  Acceptance of an increased perioperative mortality (approximately 2 %) and/or&#xD;
             morbidity (long lasting hospitalization due to prolonged air leaks)&#xD;
&#xD;
          -  COPD (GOLD guidelines) with severe obstructive ventilatory defect (FEV1 &lt;35%&#xD;
             predicted)&#xD;
&#xD;
          -  Functional aspects of lung emphysema, i.e. irreversible hyperinflation with a residual&#xD;
             volume to total lung capacity ratio (RV/TLC) of &gt;0.65 and an impaired total lung&#xD;
             diffusion capacity (DLCO), usually &lt; 40% predicted.&#xD;
&#xD;
          -  Pulmonary emphysema confirmed by high resolution computer tomography&#xD;
&#xD;
        Exclusion criteria: - Current smokers&#xD;
&#xD;
          -  Age &gt; 75years&#xD;
&#xD;
          -  &quot;Vanishing&quot; lung or diffuse lung emphysema on CT, FEV1 &lt;20% predicted and DLCO &lt;20%&#xD;
             predicted, and hypercapnia (PaCO2 &gt;7.3kPa)&#xD;
&#xD;
          -  Overt active coronary artery disease, severe left ventricular function impairment&#xD;
&#xD;
          -  Pulmonary hypertension with a mean pulmonary artery pressure &gt;35 mmHg at rest&#xD;
&#xD;
          -  Acute bronchopulmonary infection, bronchiectasis on high resolution tomography&#xD;
&#xD;
          -  Pulmonary cachexia (body mass index &lt;18kg/m2)&#xD;
&#xD;
          -  Neoplastic disease with a life expectancy of less than 2 years&#xD;
&#xD;
          -  Addiction to alcohol/drugs&#xD;
&#xD;
          -  Relevant renal (creatinine &gt;150ug/ml), active gastroenterological (GI-bleeding in the&#xD;
             previous year, abnormal liver function, active inflammatory bowel disease) or active&#xD;
             neurological disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Kohler, MD, Leading Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Pneumology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Division, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

